2024
The Million Veteran Program 1990–1991 Gulf War Era Survey: An Evaluation of Veteran Response, Characteristics, and Representativeness of the Gulf War Era Veteran Population
Harrington K, Quaden R, Steele L, Helmer D, Hauser E, Ahmed S, Aslan M, Radhakrishnan K, Honerlaw J, Nguyen X, Muralidhar S, Concato J, Cho K, Gaziano J, Whitbourne S, Program O. The Million Veteran Program 1990–1991 Gulf War Era Survey: An Evaluation of Veteran Response, Characteristics, and Representativeness of the Gulf War Era Veteran Population. International Journal Of Environmental Research And Public Health 2024, 21: 72. PMID: 38248536, PMCID: PMC10815483, DOI: 10.3390/ijerph21010072.Peer-Reviewed Original ResearchGulf War IllnessMillion Veteran ProgramVeteran populationVeterans Health Administration (VHA) servicesHealth conditionsComparable health statusLarge research cohortsVA Million Veteran ProgramSimilar medical conditionsHigher socioeconomic statusGW veteransMean ageVHA servicesHealth characteristicsMedical conditionsEligible veteransHealth statusResearch cohortCohortSocioeconomic statusVeterans' responsesVeteransVeteran ProgramBroader populationFull population
2023
Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
Yan L, Streja E, Li Y, Rajeevan N, Rowneki M, Berry K, Hynes D, Cunningham F, Huang G, Aslan M, Ioannou G, Bajema K. Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023. JAMA Network Open 2023, 6: e2331249. PMID: 37651140, PMCID: PMC10472184, DOI: 10.1001/jamanetworkopen.2023.31249.Peer-Reviewed Original ResearchConceptsCOVID-19 pharmacotherapyVeterans Health AdministrationVeterans Integrated Service NetworkSARS-CoV-2Higher Charlson Comorbidity Index scoresCharlson Comorbidity Index scoreNon-Hispanic veteransComorbidity Index scoreProportion of patientsSymptomatic COVID-19Multivariable logistic regressionCOVID-19 vaccinationCohort studyMedicare databaseVHA careUS veteransMAIN OUTCOMEMedical conditionsHispanic veteransPharmacotherapyHealth AdministrationIndex scoreCommunity careNonhospitalized personsWhite veterans
2022
Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022
Bajema K, Wang X, Hynes D, Rowneki M, Hickok A, Cunningham F, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Viglianti E, Streja E, Yan L, Aslan M, Huang G, Ioannou G. Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022. JAMA Network Open 2022, 5: e2241434. PMID: 36367727, PMCID: PMC9652752, DOI: 10.1001/jamanetworkopen.2022.41434.Peer-Reviewed Original ResearchConceptsCOVID-19 pharmacotherapySevere COVID-19SARS-CoV-2Health care systemCohort studyRisk factorsCare systemMedical conditionsCOVID-19Positive SARS-CoV-2 testVeterans Affairs Health Care SystemCOVID-19-related hospitalizationCOVID-19-related symptomsLarge integrated health care systemSARS-CoV-2 testVA health care systemIntegrated health care systemNon-Hispanic veteransModerate COVID-19Odds of receiptMultivariable logistic regressionCOVID-19 vaccinationMedical comorbiditiesMedian ageAnti-SARS